TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00886574
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg (50 mg 2T twice per day)
Study: NCT00886574
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg once a day
Study: NCT02252783
Drug: BFPET
Normalized name: Bfpet F-18
DrugBank: Bfpet F-18 (DB15424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
Study: NCT00196755
Drug: Sevelamer Hydrochloride (Renagel®)
Normalized name: sevelamer hydrochloride Oral Tablet [RenaGel]
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride three times per day with each meal
Study: NCT03855332
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See above
Study: NCT00874237
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Staccato Loxapine 10 mg single dose
Study: NCT00874237
Drug: Oral moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral moxifloxacin 400 mg
Study: NCT02683837
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered to maintain a Bispectral Index between 40 and 60
Study: NCT01346397
Drug: cyclosporine or tacrolimus
Normalized name: Tacrolimus
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: after alemtuzumab, cyclosporine or tacrolimus was administered
Study: NCT00662740
Drug: Tiotropium/Salmeterol QD
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
Study: NCT00662740
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol Inhalation Powder, hard PE capsule
Study: NCT00662740
Drug: Tiotropium/Salmeterol QD+ Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
Study: NCT00662740
Drug: Tiotropium (Spiriva®)
Normalized name: tiotropium Inhalation Powder [Spiriva]
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium, Spiriva®
Study: NCT00920764
Drug: Placebo for Atrasentan 0.2 mg/mL solution
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL oral solution, daily, 8 weeks
Study: NCT00920764
Drug: 0.25 mg Atrasentan QD
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL oral solution, daily, 8 weeks
Study: NCT00920764
Drug: 0.75 mg Atrasentan QD
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL oral solution, daily, 8 weeks
Study: NCT00920764
Drug: 1.75 mg Atrasentan QD
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL oral solution, daily, 8 weeks
Study: NCT01064570
Drug: all-trans retinoic acid (ATRA)
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01257009
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
Study: NCT01244269
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
Study: NCT01244269
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate 20mg three times daily for a total of 7 doses.
Study: NCT01542125
Drug: Liposomal Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4% Liposomal Lidocaine
Study: NCT03725930
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clonidine intranasal premedication in preschool infants
Study: NCT04342156
Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab
Normalized name: hydroxychloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet of Hydroxychloroquine sulfate
Study: NCT00313157
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00970580
Drug: BIIB022 With Paclitaxel and Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
Study: NCT00313157
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00313157
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00313157
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00565448
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study: NCT00565448
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study: NCT00565448
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:solution for infusion~Route of administration:intravenous
Study: NCT02393157
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
Study: NCT02393157
Drug: Liposomal ARA-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Will be given intrathecally for both prophylaxis and treatment of CNS disease.
Study: NCT02393157
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
Study: NCT02393157
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
Study: NCT02393157
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
Study: NCT02553122
Drug: Evicel
Normalized name: Evicel
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
Study: NCT00907751
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
Study: NCT03456648
Drug: apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: non-vitamin K oral anticoagulant (NOAC)
Study: NCT04961268
Drug: TraMADol 50 Mg Oral Tablet
Normalized name: traMADol 50 mg oral tablet
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study: NCT04961268
Drug: Tramadol 100 MG Oral Tablet
Normalized name: tramadol 100 MG Oral Tablet
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients were randomly given the medication by mouth 60 min before administering IANB.
Study: NCT00908024
Drug: BMS-754807
Normalized name: BMS-754807
DrugBank: BMS-754807 (DB15399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
Study: NCT00908024
Drug: cetuximab (Erbitux®)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
Study: NCT02761395
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20-40 mg/kg/day orally
Study: NCT01652742
Drug: BI 135585 XX
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single dose
Study: NCT02705807
Drug: FLOLAN injection with currently marketed diluent
Normalized name: epoprostenol Injection [Flolan]
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen \[pH\] 10.2 - 10.8 diluent) for Injection.
Study: NCT02705807
Drug: FLOLAN injection with reformulated diluent
Normalized name: epoprostenol Injection [Flolan]
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
Study: NCT01037491
Drug: rabeprazole plus aspirin versus rabeprazole plus clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
Study: NCT03854929
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor
Study: NCT00440479
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose as determined (observational study) by treating physician
Study: NCT03111485
Drug: Sinemet CR
Normalized name: Sinemet CR
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule 250 mg / 50 mg taken at bedtime
Study: NCT01180569
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient enrollment FNA of palpable lymph node prior to escalation phase~Escalation phase of Lenalidomide:~Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase~Treatment phase of Lenalidomide:~15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles
Study: NCT00020579
Drug: entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04792944
Drug: Urokinase
Normalized name: Urokinase
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Washing the subarachnoid clot induced by a subarachnoid haemorrhage aneurysmal bleeding with urokinase after aneurysm clipping
Study: NCT04553510
Drug: Bevacizumab and steroid
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
Study: NCT04553510
Drug: Bevacizumab and placebo
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
Study: NCT02492477
Drug: restoration of PORT-A-CATH® with Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
Study: NCT01624064
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5-20 mg/day
Study: NCT00454285
Drug: Effect of Amoxicillin on bacteremia following a single-tooth extraction
Normalized name: Sus scrofa tooth preparation
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer Amoxicillin 1 hour prior to single-tooth extraction.
Study: NCT01034592
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg/wk up to 5 mg 3x/wk
Study: NCT01987960
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 to 3 mg/day, once daily dose, tablets, orally
Study: NCT00580372
Drug: VAD
Normalized name: Uvadex
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
Study: NCT00580372
Drug: EDAP
Normalized name: Edap
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
Study: NCT00580372
Drug: Maintenance
Normalized name: Xcopri Maintenance Pack
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 months after Transplant 2: Intron A 3 X 10\^6 units /m2 M-W-F subcutaneously until relapse
Study: NCT01582295
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose 40 mg daily
Study: NCT02569073
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol 5 mg, every other night, orally
Study: NCT00946504
Drug: Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00946504
Drug: Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
Normalized name: glipizide 10 MG [Glucotrol]
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00304291
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04446962
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
Study: NCT04446962
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
Study: NCT04029610
Drug: lidocaine and adrenalin
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine and adrenalin
Study: NCT04029610
Drug: lidocaine and arterial blockage
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine and arterial blockage
Study: NCT01565096
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000 mg BID
Study: NCT01565096
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50 mg twice daily
Study: NCT01565096
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride at individual dose
Study: NCT00818337
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
Study: NCT03361228
Drug: INCB001158
Normalized name: INCB001158
DrugBank: CB-1158 (DB15286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
Study: NCT03361228
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat at the protocol-defined dose administered orally twice daily.
Study: NCT03361228
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
Study: NCT01606800
Drug: PEG-IFN alfa-2b
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
Study: NCT01606800
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin 200 mg capsules administered orally daily based on weight
Study: NCT03323541
Drug: Filgrastim Prefilled Syringe [Zarzio®]
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils \>1 giga/l)
Study: NCT04173273
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose A taken by mouth, once daily.
Study: NCT04173273
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B taken by mouth, once daily.
Study: NCT00745823
Drug: Comparator: Raltegravir 400 mg b.i.d.
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
Study: NCT03432897
Drug: Olaparib Pill
Normalized name: olaparib Pill
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg BID
Study: NCT00193622
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00193622
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00745823
Drug: Experimental: Raltegravir 800 mg q.d.
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
Study: NCT03536884
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study: NCT03536884
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive secukinumab at pre-specified time-points.
Study: NCT04346654
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
Study: NCT04346654
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
Study: NCT02590185
Drug: cocktail probe drugs
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~* A capsule of omeprazole ABBOTT® 10mg~* 10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~* 1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~* A tablet of fexofenadine Zentiva® 120mg
Study: NCT00360360
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
Study: NCT00360360
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6.0 IV Day 1
Study: NCT00360360
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15mg/kg IV infusion,Day 1
Study: NCT00360360
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg by mouth daily
Study: NCT01358565
Drug: Fx-1006A
Normalized name: Fx-1006A
DrugBank: Fx-1006A (DB05352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
Study: NCT03693430
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
Study: NCT01092351
Drug: Nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg retard capsules to be taken twice daily for seven days
Study: NCT00455351
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing dosing, phase I
Study: NCT03576612
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO days 1-14; 1-3 days post surgery